Author

R. D. May

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Fowler· 1 shared B. P. Kemp· 1 shared C. Colley· 1 shared C. E. C. Huntington· 1 shared C. Hollins· 1 shared C. K. F. Li· 1 shared D. A. Sims· 1 shared D. C. Lowe· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Fowler

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Patient phenotypes and their relation to TNFα signaling and immune cell composition in critical illness and autoimmune disease

V. Krishna, H. Banie, N. Conceicao-Neto, Y. Murata, I. Verbrugge, V. Trifonov, R. Martinez, V. Murali, Y.-c. Lee, R. D. May, I. Najera, A. Fowler, C. K. F. Li

The paper identifies a hyper-inflammatory phenotype linked to TNF signaling and mature neutrophils in critical illness and autoimmune disease using machine learning and patient data.

bioRxiv · Oct 30, 2023 · PreprintImmunology

Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

E. England, D. G. Rees, I. C. Scott, S. Carmen, D. T. Y. Chan, C. E. C. Huntington, K. F. Houslay, T. Erngren, M. Penney, J. B. Majithiya, L. Rapley, D. A. Sims, C. Hollins, E. C. Hinchy, M. D. Strain, , E. S. Cohen

This paper describes tozorakimab, an anti-IL-33 antibody that inhibits both reduced and oxidized IL-33 signaling pathways to reduce inflammation and epithelial dysfunction.

bioRxiv · Feb 28, 2023Immunology